Longbio Pharma registers Phase 3 trial of LP-003 Injection in chronic spontaneous urticaria
The study plans to enroll 514 participants and plans to start on December 7, 2026. It is a multicenter, randomized, double-blind, active-controlled Phase III trial comparing LP-003 Injection with omalizumab in patients who remain symptomatic despite H1 antihistamine treatment.
Primary source
ClinicalTrials.gov registry record, November 18, 2026
A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
Machine-summarized from the source above; not independently reported. How we use automation